Abstract:Immunodeficient mice transplanted subcutaneously with human tumors (xenografts) are a widely used model of preclinical efficacy in the discovery and development of anti-cancer agents. We performed a retrospective population pharmacokinetic-pharmacodynamic (PK-PD) analysis of xenograft efficacy data that accounts for differences in clinical and preclinical drug exposure in order to improve their predictive value. In addition, we investigated the ability of xenograft studies to predict clinical response with newer molecular targeted agents. Data from preclinical and clinical studies with three cytotoxic chemotherapeutic agents (docetaxel, carboplatin, and 5-fluorouracil) and five molecular targeted agents (erlotinib, sunitnib, dasatinib, trastuzumab, and vismodegib) were included in this analysis. Anti-cancer agents were administered at a range of doses to xenograft mice bearing tumors relevant to the cancer of interest. No correlation was observed when comparing clinical response to % tumor growth inhibition (%TGI) at the maximum tolerated dose (MTD) in mice. PK-PD modeling was used to simulate %TGI in xenografts using human exposures at clinically relevant doses. These simulated %TGI in xenografts driven by human drug exposures were found to correlate (r=0.92; p=0.0005) with clinical response, illustrating the importance of taking into account species differences in drug exposure when interpreting xenograft data. Distinct differences were observed in the anti-tumor activity of sunitinib in Colo205 colorectal (simulated %TGI = 64%) and 786-O renal cell adenocarcinoma (simulated %TGI = 81%) xenografts, and vismodegib in medulloblastoma allografts (simulated %TGI =102%) and D5123 colorectal xenografts (simulated %TGI = 33%). These differences were consistent with the underlying biology of these models and demonstrate the importance of understanding tumor biology when selecting relevant xenograft models for molecular targeted agents. Based on these analyzes, agents that lead to greater than 60% tumor growth inhibition in preclinical models at clinically relevant exposures are more likely to lead to responses in the clinic. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A11.

Figure S2 from Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models

Supplementary Figure 6 from Enhancement of Nab-Paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer

Supplementary Fig.S12 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Supplementary Figure 5 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan Through Liposomal Formulation and Antiangiogenic Combination Therapy

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Figure S6 from Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma <i>in Vitro</i> and Patient-Derived Xenografts <i>in Vivo</i>

Establishing a Peritoneal Dissemination Xenograft Mouse Model for Survival Outcome Assessment of Experimental Gastric Cancer.

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

Supplementary Figure 1 from <i>pten</i> Expression As a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer

Abstract A11: Antitumor activity of targeted and cytotoxic agents in xenograft models correlates with clinical response: A pharmacokinetic-pharmacodynamic analysis.

Supplementary Figure 4 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>in Vitro</i> and <i>in Vivo</i> Models of Non–Small Cell Lung Cancer

Supplementary Figure S2 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia

Establishment of Orthotopic Transplantation Model of MKN-45 Human Gastric Cancer and Evaluation of the Efficacy of Paclitaxel in This Model

A Tissue-Engineered Gastric Cancer Model For Mechanistic Study Of Anti-Tumor Drugs

Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models

New Mouse Xenograft Model Modulated by Tumor-Associated Fibroblasts for Human Multi-Drug Resistance in Cancer

Gastric Cancer Assembloids Derived from Patient‐Derived Xenografts: A Preclinical Model for Therapeutic Drug Screening (Small Methods 9/2024)

Responsiveness of Human Gastric Tumors Implanted in Nude Mice to Clinically Equivalent Doses of Various Antitumor Agents

Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC